{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:34:59Z","timestamp":1793018099182,"version":"4.5.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100010609","name":"Gda\u0144ski Uniwersytet Medyczny","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010609","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s13555-026-01909-5","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:38:23Z","timestamp":1790015903000},"page":"5325-5360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hidradenitis Suppurativa from Preconception to Lactation: Clinical Treatment Decision-Making Review"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-5705","authenticated-orcid":false,"given":"Mi\u0142osz","family":"Lewandowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiktoria","family":"Szablewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyna","family":"S\u0142awi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Kujach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman J.","family":"Nowicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wioletta","family":"Bara\u0144ska-Rybak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"issue":"6","key":"1909_CR1","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/DDG.15412","volume":"22","author":"CC Zouboulis","year":"2024","unstructured":"Zouboulis CC, Bechara FG, Fritz K, et al. S2k guideline for the treatment of hidradenitis suppurativa \/ acne inversa - Short version. J Dtsch Dermatol Ges. 2024;22(6):868\u201389. https:\/\/doi.org\/10.1111\/DDG.15412.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1909_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004321","author":"CJ Sayed","year":"2021","unstructured":"Sayed CJ, Hsiao JL, Okun MM. Clinical expert series clinical epidemiology and management of Hidradenitis suppurativa. Obstet Gynecol. 2021. https:\/\/doi.org\/10.1097\/AOG.0000000000004321.","journal-title":"Obstet Gynecol"},{"issue":"8","key":"1909_CR3","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/JAMADERMATOL.2017.0201","volume":"153","author":"A Garg","year":"2017","unstructured":"Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex- and age-adjusted population analysis of prevalence estimates for Hidradenitis suppurativa in the United States. JAMA Dermatol. 2017;153(8):760\u20134. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2017.0201.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"1909_CR4","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1001\/JAMADERMATOL.2021.1677","volume":"157","author":"A Jfri","year":"2021","unstructured":"Jfri A, Nassim D, O\u2019Brien E, Gulliver W, Nikolakis G, Zouboulis CC. Prevalence of Hidradenitis suppurativa: a systematic review and meta-regression analysis. JAMA Dermatol. 2021;157(8):924\u201331. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2021.1677.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1909_CR5","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1159\/000517283","volume":"238","author":"JR Seivright","year":"2022","unstructured":"Seivright JR, Villa NM, Grogan T, et al. Impact of pregnancy on Hidradenitis suppurativa disease course: a systematic review and meta-analysis. Dermatology. 2022;238(2):260\u20136. https:\/\/doi.org\/10.1159\/000517283.","journal-title":"Dermatology"},{"issue":"7","key":"1909_CR6","doi-asserted-by":"publisher","first-page":"706","DOI":"10.36849\/JDD.6818","volume":"22","author":"GM Rivin","year":"2023","unstructured":"Rivin GM, Fleischer AB. Women of childbearing age with Hidradenitis suppurativa frequently prescribed medications with pregnancy risk. J Drugs Dermatol. 2023;22(7):706\u20139. https:\/\/doi.org\/10.36849\/JDD.6818.","journal-title":"J Drugs Dermatol"},{"key":"1909_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00935-x","author":"R Ghanshani","year":"2025","unstructured":"Ghanshani R, Lee K, Crew AB, Shi VY, Hsiao JL. A guide to the management of hidradenitis suppurativa in pregnancy and lactation. Am J Clin Dermatol. 2025. https:\/\/doi.org\/10.1007\/s40257-025-00935-x.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1909_CR8","doi-asserted-by":"publisher","first-page":"e14674","DOI":"10.1111\/DTH.14674","volume":"34","author":"EK Collier","year":"2021","unstructured":"Collier EK, Seivright JR, Shi VY, Hsiao JL. Pregnancy and breastfeeding in hidradenitis suppurativa: a review of medication safety. Dermatol Ther. 2021;34(1):e14674. https:\/\/doi.org\/10.1111\/DTH.14674.","journal-title":"Dermatol Ther"},{"issue":"5","key":"1909_CR9","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/J.GASTHA.2022.04.009","volume":"1","author":"B Truta","year":"2022","unstructured":"Truta B, Canner JK, Fang SH, Efron JE, Safar B. Outcomes of continuation vs discontinuation of adalimumab therapy during third trimester of pregnancy in inflammatory bowel disease. Gastro hep Adv. 2022;1(5):785\u201391. https:\/\/doi.org\/10.1016\/J.GASTHA.2022.04.009.","journal-title":"Gastro hep Adv"},{"issue":"7","key":"1909_CR10","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/IJD.17672","volume":"64","author":"L \u00d6zbek","year":"2025","unstructured":"\u00d6zbek L, G\u00fcldan M, Alpsoy E, Vural S. Hidradenitis suppurativa treatment during pregnancy and lactation: navigating challenges. Int J Dermatol. 2025;64(7):1173\u201385. https:\/\/doi.org\/10.1111\/IJD.17672.","journal-title":"Int J Dermatol"},{"issue":"4","key":"1909_CR11","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1159\/000530758","volume":"239","author":"P Aarts","year":"2023","unstructured":"Aarts P, Reeves JL, Ardon CB, Van Der Zee HH, Prens EP. Clindamycin-benzoyl peroxide gel compared with clindamycin lotion for hidradenitis suppurativa: a randomized controlled assessor-blinded intra-patient pilot study. Dermatology. 2023;239(4):670. https:\/\/doi.org\/10.1159\/000530758.","journal-title":"Dermatology"},{"issue":"2","key":"1909_CR12","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3122\/JABFM.2016.02.150165","volume":"29","author":"AL Chien","year":"2016","unstructured":"Chien AL, Qi J, Rainer B, Sachs DL, Helfrich YR. Treatment of acne in pregnancy. J Am Board Fam Med. 2016;29(2):254\u201362. https:\/\/doi.org\/10.3122\/JABFM.2016.02.150165.","journal-title":"J Am Board Fam Med"},{"issue":"7","key":"1909_CR13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2165\/00128071-200304070-00004","volume":"4","author":"A Akhavan","year":"2003","unstructured":"Akhavan A, Bershad S. Topical acne drugs: review of clinical properties, systemic exposure, and safety. Am J Clin Dermatol. 2003;4(7):473\u201392. https:\/\/doi.org\/10.2165\/00128071-200304070-00004.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1909_CR14","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1159\/000530758","volume":"239","author":"P Aarts","year":"2023","unstructured":"Aarts P, Reeves JL, Ardon CB, Van Der Zee HH, Prens EP. Clindamycin-benzoyl peroxide gel compared with clindamycin lotion for hidradenitis suppurativa: a randomized controlled assessor-blinded intra-patient pilot study. Dermatology. 2023;239(4):670\u20134. https:\/\/doi.org\/10.1159\/000530758.","journal-title":"Dermatology"},{"issue":"6","key":"1909_CR15","doi-asserted-by":"publisher","first-page":"e15439","DOI":"10.1111\/DTH.15439","volume":"35","author":"E Molinelli","year":"2022","unstructured":"Molinelli E, Brisigotti V, Simonetti O, et al. Efficacy and safety of topical resorcinol 15% versus topical clindamycin 1% in the management of mild-to-moderate hidradenitis suppurativa: a retrospective study. Dermatol Ther. 2022;35(6):e15439. https:\/\/doi.org\/10.1111\/DTH.15439.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1909_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.25259\/IJPGD_108_2023","volume":"2","author":"AG C","year":"2024","unstructured":"C AG, Chhabra N, C AG, Chhabra N. Resorcinol in dermatology. Indian J Postgrad Dermatol. 2024;2(1):20\u20133. https:\/\/doi.org\/10.25259\/IJPGD_108_2023.","journal-title":"Indian J Postgrad Dermatol"},{"issue":"1","key":"1909_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/10915810701876687","volume":"27","author":"F Welsch","year":"2008","unstructured":"Welsch F. Routes and modes of administration of resorcinol and their relationship to potential manifestations of thyroid gland toxicity in animals and man. Int J Toxicol. 2008;27(1):59\u201363. https:\/\/doi.org\/10.1080\/10915810701876687.","journal-title":"Int J Toxicol"},{"issue":"4","key":"1909_CR18","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/J.JAAD.2023.10.072","volume":"91","author":"P McMullan","year":"2024","unstructured":"McMullan P, Yaghi M, Truong TM, Rothe M, Murase J, Grant-Kels JM. Safety of dermatologic medications in pregnancy and lactation: an update - part I: pregnancy. J Am Acad Dermatol. 2024;91(4):619\u201348. https:\/\/doi.org\/10.1016\/J.JAAD.2023.10.072.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1909_CR19","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/J.JAAD.2023.10.071","volume":"91","author":"M Yaghi","year":"2024","unstructured":"Yaghi M, McMullan P, Truong TM, Rothe M, Murase J, Grant-Kels JM. Safety of dermatologic medications in pregnancy and lactation: an update-part II: lactation. J Am Acad Dermatol. 2024;91(4):651\u201368. https:\/\/doi.org\/10.1016\/J.JAAD.2023.10.071.","journal-title":"J Am Acad Dermatol"},{"key":"1909_CR20","doi-asserted-by":"publisher","DOI":"10.1177\/2040622319830646","volume":"10","author":"JW Frew","year":"2019","unstructured":"Frew JW, Hawkes JE, Krueger JG. Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms. Ther Adv Chronic Dis. 2019;10:2040622319830646. https:\/\/doi.org\/10.1177\/2040622319830646.","journal-title":"Ther Adv Chronic Dis"},{"issue":"3","key":"1909_CR21","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/J.IJGO.2010.09.009","volume":"112","author":"L Pereira","year":"2011","unstructured":"Pereira L, Chipato T, Mashu A, et al. Randomized study of vaginal and neonatal cleansing with 1% chlorhexidine. Int J Gynaecol Obstet. 2011;112(3):234\u20138. https:\/\/doi.org\/10.1016\/J.IJGO.2010.09.009.","journal-title":"Int J Gynaecol Obstet"},{"key":"1909_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003520.PUB2","author":"BC Stade","year":"2004","unstructured":"Stade BC, Shah VS, Ohlsson A. Vaginal chlorhexidine during labour to prevent early-onset neonatal group B streptococcal infection. Cochrane Database Syst Rev. 2004. https:\/\/doi.org\/10.1002\/14651858.CD003520.PUB2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"1909_CR23","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/JDV.20472","volume":"39","author":"CC Zouboulis","year":"2025","unstructured":"Zouboulis CC, Bechara FG, Benhadou F, et al. European S2k guidelines for hidradenitis suppurativa\/acne inversa part 2: treatment. J Eur Acad Dermatol Venereol. 2025;39(5):899\u2013941. https:\/\/doi.org\/10.1111\/JDV.20472.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1909_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/AJD.14388","volume":"66","author":"J Frew","year":"2025","unstructured":"Frew J, Smith A, Penas PF, et al. Australasian hidradenitis suppurativa management guidelines. Australas J Dermatol. 2025;66(2):75\u201389. https:\/\/doi.org\/10.1111\/AJD.14388.","journal-title":"Australas J Dermatol"},{"issue":"4","key":"1909_CR25","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/J.JAAD.2024.11.071","volume":"92","author":"R Alhusayen","year":"2025","unstructured":"Alhusayen R, Dienes S, Lam M, et al. North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations. J Am Acad Dermatol. 2025;92(4):825\u201352. https:\/\/doi.org\/10.1016\/J.JAAD.2024.11.071.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1909_CR26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/J.IJWD.2019.11.004","volume":"6","author":"E Nesbitt","year":"2019","unstructured":"Nesbitt E, Clements S, Driscoll M. A concise clinician\u2019s guide to therapy for hidradenitis suppurativa. Int J Womens Dermatol. 2019;6(2):80\u20134. https:\/\/doi.org\/10.1016\/J.IJWD.2019.11.004.","journal-title":"Int J Womens Dermatol"},{"issue":"4","key":"1909_CR27","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/PHAR.70010","volume":"45","author":"J Nguyen","year":"2025","unstructured":"Nguyen J, Madonia V, Bland CM, et al. A review of antibiotic safety in pregnancy-2025 update. Pharmacotherapy. 2025;45(4):227\u201337. https:\/\/doi.org\/10.1002\/PHAR.70010.","journal-title":"Pharmacotherapy"},{"key":"1909_CR28","doi-asserted-by":"publisher","unstructured":"Herman TF, Hashmi MF. Cephalexin. Kucers the use of antibiotics: a clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs, Seventh Edition. 2023:361\u2013369. https:\/\/doi.org\/10.1201\/9781315152110","DOI":"10.1201\/9781315152110"},{"issue":"3","key":"1909_CR29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/J.1651-2227.1981.TB16553.X","volume":"70","author":"DA Kafetzis","year":"1981","unstructured":"Kafetzis DA, Siafas CA, Georgakopoulos PA, Papadatos CJ. Passage of cephalosporins and amoxicillin into the breast milk. Acta Paediatr Scand. 1981;70(3):285\u20138. https:\/\/doi.org\/10.1111\/J.1651-2227.1981.TB16553.X.","journal-title":"Acta Paediatr Scand"},{"key":"1909_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.JDCR.2023.04.025","volume":"37","author":"R Masson","year":"2023","unstructured":"Masson R, Seivright J, Shih T, et al. Trimethoprim\/sulfamethoxazole and cephalexin combination therapy in hidradenitis suppurativa patients: a series of 16 cases. JAAD Case Rep. 2023;37:1\u20134. https:\/\/doi.org\/10.1016\/J.JDCR.2023.04.025.","journal-title":"JAAD Case Rep"},{"key":"1909_CR31","doi-asserted-by":"publisher","DOI":"10.1208\/S12248-025-01109-7","author":"MC Huang","year":"2025","unstructured":"Huang MC, Macente J, Nauwelaerts N, et al. Population pharmacokinetic modeling of amoxicillin in plasma and milk in lactating G\u00f6ttingen minipigs - a contribution from the ConcePTION project. AAPS J. 2025. https:\/\/doi.org\/10.1208\/S12248-025-01109-7.","journal-title":"AAPS J"},{"issue":"2","key":"1909_CR32","doi-asserted-by":"publisher","first-page":"170","DOI":"10.2174\/2589977515666221212150311","volume":"15","author":"N Bahri","year":"2023","unstructured":"Bahri N, Dashti S, Mohammadzadeh A, Sharifi N, Hadizadeh-Talasaz F, Mardeneh J. Relationship between amoxicillin use in pregnancy and congenital anomalies: a systematic review. Curr Drug Res Rev. 2023;15(2):170\u20136. https:\/\/doi.org\/10.2174\/2589977515666221212150311.","journal-title":"Curr Drug Res Rev"},{"issue":"3","key":"1909_CR33","doi-asserted-by":"publisher","first-page":"e14919","DOI":"10.1111\/DTH.14919","volume":"34","author":"M Iannone","year":"2021","unstructured":"Iannone M, Janowska A, Bartolomei G, et al. Systemic antibiotics in hidradenitis suppurativa: efficacy and effects of body mass index and smoking pack-year on the response to therapy. Dermatol Ther. 2021;34(3):e14919. https:\/\/doi.org\/10.1111\/DTH.14919.","journal-title":"Dermatol Ther."},{"issue":"5","key":"1909_CR34","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1111\/JDV.17069","volume":"35","author":"HC Ring","year":"2021","unstructured":"Ring HC, Knudsen A, Thomsen SF. Metronidazole for hidradenitis suppurativa: future potential treatment applications. J Eur Acad Dermatol Venereol. 2021;35(5):e323\u20134. https:\/\/doi.org\/10.1111\/JDV.17069.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1909_CR35","unstructured":"Can we use metronidazole during pregnancy and breastfeeding? putting an end to the controversy - PubMed. Accessed February 11, 2026. https:\/\/pubmed.ncbi.nlm.nih.gov\/10845129\/."},{"issue":"4-6","key":"1909_CR36","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1080\/07399332.2021.1882462","volume":"42","author":"OC Nwosu","year":"2021","unstructured":"Nwosu OC, Bloom K. The safety of metronidazole in pregnancy. Health Care Women Int. 2021;42(4\u20136):726\u201338. https:\/\/doi.org\/10.1080\/07399332.2021.1882462.","journal-title":"Health Care Women Int"},{"key":"1909_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/J.EUROX.2021.100128","author":"P Ajiji","year":"2021","unstructured":"Ajiji P, Uzunali A, Ripoche E, Vittaz E, Vial T, Maison P. Investigating the efficacy and safety of metronidazole during pregnancy: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol X. 2021. https:\/\/doi.org\/10.1016\/J.EUROX.2021.100128.","journal-title":"Eur J Obstet Gynecol Reprod Biol X"},{"issue":"1","key":"1909_CR38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/OMCR\/OMY111","volume":"2019","author":"ASO Tang","year":"2019","unstructured":"Tang ASO, Yeo ST, Teh YC, Kho WM, Chew LP, Muniandy P. The mystery of \u201csaturation gap\u201d: a case of dapsone-induced methaemoglobinemia in a pregnant mother with leprosy. Oxf Med Case Rep. 2019;2019(1):8\u201310. https:\/\/doi.org\/10.1093\/OMCR\/OMY111.","journal-title":"Oxf Med Case Rep"},{"issue":"4","key":"1909_CR39","doi-asserted-by":"publisher","first-page":"465","DOI":"10.7326\/0003-4819-96-4-465","volume":"96","author":"SW Sanders","year":"1982","unstructured":"Sanders SW, Zone JJ, Foltz RL, Tolman KG, Rollins DE. Hemolytic anemia induced by dapsone transmitted through breast milk. Ann Intern Med. 1982;96(4):465\u20136. https:\/\/doi.org\/10.7326\/0003-4819-96-4-465.","journal-title":"Ann Intern Med"},{"issue":"7","key":"1909_CR40","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/IJD.15459","volume":"60","author":"AHR J\u00f8rgensen","year":"2021","unstructured":"J\u00f8rgensen AHR, Yao Y, Thomsen SF, Ring HC. Treatment of hidradenitis suppurativa with tetracycline, doxycycline, or lymecycline: a prospective study. Int J Dermatol. 2021;60(7):785\u201391. https:\/\/doi.org\/10.1111\/IJD.15459.","journal-title":"Int J Dermatol"},{"issue":"3","key":"1909_CR41","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/JAC\/DKX420","volume":"73","author":"H Peyriere","year":"2018","unstructured":"Peyriere H, Makinson A, Marchandin H, Reynes J. Doxycycline in the management of sexually transmitted infections. J Antimicrob Chemother. 2018;73(3):553\u201363. https:\/\/doi.org\/10.1093\/JAC\/DKX420.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"1909_CR42","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1517\/14740338.2016.1133584","volume":"15","author":"R Cross","year":"2016","unstructured":"Cross R, Ling C, Day NPJ, Mcgready R, Paris DH. Revisiting doxycycline in pregnancy and early childhood \u2013 time to rebuild its reputation? Expert Opin Drug Saf. 2016;15(3):367. https:\/\/doi.org\/10.1517\/14740338.2016.1133584.","journal-title":"Expert Opin Drug Saf"},{"issue":"70 Suppl 1","key":"1909_CR43","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1093\/CID\/CIZ1231","volume":"70","author":"PA Yu","year":"2020","unstructured":"Yu PA, Tran EL, Parker CM, et al. Safety of antimicrobials during pregnancy: a systematic review of antimicrobials considered for treatment and postexposure prophylaxis of plague. Clin Infect Dis. 2020;70(70 Suppl 1):S37\u201350. https:\/\/doi.org\/10.1093\/CID\/CIZ1231.","journal-title":"Clin Infect Dis"},{"key":"1909_CR44","unstructured":"Tetracycline. Drugs and Lactation Database (LactMed\u00ae). Published online June 15, 2025. Accessed May 7, 2026. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK501108\/."},{"key":"1909_CR45","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2024.47322","author":"JN van den Anker","year":"2024","unstructured":"van den Anker JN. Use of tetracyclines during the different stages of pregnancy. JAMA Netw Open. 2024. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2024.47322.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"1909_CR46","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/PHAR.2732","volume":"43","author":"SP Thomas","year":"2022","unstructured":"Thomas SP, Denizer E, Zuffa S, et al. Transfer of antibiotics and their metabolites in human milk: implications for infant health and microbiota. Pharmacotherapy. 2022;43(5):442. https:\/\/doi.org\/10.1002\/PHAR.2732.","journal-title":"Pharmacotherapy"},{"issue":"6","key":"1909_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ANTIBIOTICS12060978","volume":"12","author":"E Molinelli","year":"2023","unstructured":"Molinelli E, De Simoni E, Candelora M, et al. Systemic antibiotic therapy in hidradenitis suppurativa: a review on treatment landscape and current issues. Antibiot (Basel). 2023;12(6):978. https:\/\/doi.org\/10.3390\/ANTIBIOTICS12060978.","journal-title":"Antibiot (Basel)"},{"issue":"4","key":"1909_CR48","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1097\/AOG.0000000000004321","volume":"137","author":"CJ Sayed","year":"2021","unstructured":"Sayed CJ, Hsiao JL, Okun MM. Clinical epidemiology and management of hidradenitis suppurativa. Obstet Gynecol. 2021;137(4):731\u201346. https:\/\/doi.org\/10.1097\/AOG.0000000000004321.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"1909_CR49","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/J.DET.2015.08.013","volume":"34","author":"V Bettoli","year":"2016","unstructured":"Bettoli V, Join-Lambert O, Nassif A. Antibiotic treatment of hidradenitis suppurativa. Dermatol Clin. 2016;34(1):81\u20139. https:\/\/doi.org\/10.1016\/J.DET.2015.08.013.","journal-title":"Dermatol Clin"},{"key":"1909_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-018-2383-8","author":"A Ziv","year":"2018","unstructured":"Ziv A, Masarwa R, Perlman A, Ziv D, Matok I. Pregnancy outcomes following exposure to quinolone antibiotics \u2013 a systematic-review and meta-analysis. Pharm Res. 2018. https:\/\/doi.org\/10.1007\/s11095-018-2383-8.","journal-title":"Pharm Res"},{"issue":"9","key":"1909_CR51","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/1471-0528.15119","volume":"125","author":"E Yefet","year":"2018","unstructured":"Yefet E, Schwartz N, Chazan B, Salim R, Romano S, Nachum Z. The safety of quinolones and fluoroquinolones in pregnancy: a meta-analysis. BJOG. 2018;125(9):1069\u201376. https:\/\/doi.org\/10.1111\/1471-0528.15119.","journal-title":"BJOG"},{"key":"1909_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/J.HELIYON.2024.E37547","author":"D Xiang","year":"2024","unstructured":"Xiang D, Xie W, Cheng G, Yue M, Du X, Jiang J. Pregnancy related adverse events and congenital disorders associated with fluoroquinolones: a real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS). Heliyon. 2024. https:\/\/doi.org\/10.1016\/J.HELIYON.2024.E37547.","journal-title":"Heliyon"},{"issue":"4","key":"1909_CR53","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/J.IJWD.2019.05.002","volume":"5","author":"YP Koh","year":"2019","unstructured":"Koh YP, Tian EA, Oon HH. New changes in pregnancy and lactation labelling: review of dermatologic drugs. Int J Womens Dermatol. 2019;5(4):216\u201326. https:\/\/doi.org\/10.1016\/J.IJWD.2019.05.002.","journal-title":"Int J Womens Dermatol"},{"key":"1909_CR54","unstructured":"Sulfamethoxazole\/Trimethoprim (Bactrim\u00ae or Septra\u00ae). Published online 2024. Accessed February 19, 2026. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK582966\/."},{"issue":"6","key":"1909_CR55","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/BCP.13542","volume":"84","author":"FT Muanda","year":"2018","unstructured":"Muanda FT, Sheehy O, B\u00e9rard A. Use of trimethoprim\u2013sulfamethoxazole during pregnancy and risk of spontaneous abortion: a nested case control study. Br J Clin Pharmacol. 2018;84(6):1198. https:\/\/doi.org\/10.1111\/BCP.13542.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1909_CR56","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1053\/J.GASTRO.2020.11.038","volume":"160","author":"U Mahadevan","year":"2021","unstructured":"Mahadevan U, Long MD, Kane SV, et al. Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterology. 2021;160(4):1131\u20139. https:\/\/doi.org\/10.1053\/J.GASTRO.2020.11.038.","journal-title":"Gastroenterology"},{"issue":"5","key":"1909_CR57","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/J.GASTHA.2022.04.009","volume":"1","author":"B Truta","year":"2022","unstructured":"Truta B, Canner JK, Fang SH, Efron JE, Safar B. Outcomes of continuation vs discontinuation of adalimumab therapy during third trimester of pregnancy in inflammatory bowel disease. Gastro Hep Adv. 2022;1(5):785\u201391. https:\/\/doi.org\/10.1016\/J.GASTHA.2022.04.009.","journal-title":"Gastro Hep Adv"},{"issue":"3","key":"1909_CR58","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/J.CGH.2012.11.011","volume":"11","author":"U Mahadevan","year":"2013","unstructured":"Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(3):286\u201392. https:\/\/doi.org\/10.1016\/J.CGH.2012.11.011.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1909_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0223603","author":"CD Chambers","year":"2019","unstructured":"Chambers CD, Johnson DL, Xu R, et al. Birth outcomes in women who have taken adalimumab in pregnancy: a prospective cohort study. PLoS ONE. 2019. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0223603.","journal-title":"PLoS ONE"},{"issue":"5","key":"1909_CR60","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/ANNRHEUMDIS-2015-208840","volume":"75","author":"CG Skorpen","year":"2016","unstructured":"Skorpen CG, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795\u2013810. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2015-208840.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1909_CR61","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/art.41191","volume":"72","author":"LR Sammaritano","year":"2020","unstructured":"Sammaritano LR, Bermas BL, Chakravarty EE, et al. American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2020;72(4):529\u201356. https:\/\/doi.org\/10.1002\/art.41191.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"1909_CR62","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1093\/RHEUMATOLOGY\/KEAC551","volume":"62","author":"MD Russell","year":"2023","unstructured":"Russell MD, Dey M, Flint J, et al. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatol (Oxford). 2023;62(4):e48\u201388. https:\/\/doi.org\/10.1093\/RHEUMATOLOGY\/KEAC551.","journal-title":"Rheumatol (Oxford)"},{"issue":"10","key":"1909_CR63","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1111\/APT.14040","volume":"45","author":"CH Seow","year":"2017","unstructured":"Seow CH, Leung Y, Vande Casteele N, et al. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(10):1329\u201338. https:\/\/doi.org\/10.1111\/APT.14040.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"1909_CR64","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/ART.41191","volume":"72","author":"LR Sammaritano","year":"2020","unstructured":"Sammaritano LR, Bermas BL, Chakravarty EE, et al. American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2020;72(4):529\u201356. https:\/\/doi.org\/10.1002\/ART.41191.","journal-title":"Arthritis Rheumatol"},{"issue":"22","key":"1909_CR65","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026190","volume":"100","author":"JW Lu","year":"2021","unstructured":"Lu JW, Huang YW, Chen TL. Efficacy and safety of adalimumab in hidradenitis suppurativa: a systematic review and meta-analysis of randomized controlled trials. Med (Baltim). 2021;100(22):e26190. https:\/\/doi.org\/10.1097\/MD.0000000000026190.","journal-title":"Med (Baltim)"},{"issue":"10378","key":"1909_CR66","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(23)00022-3.","journal-title":"Lancet"},{"key":"1909_CR67","doi-asserted-by":"publisher","unstructured":"Aboobacker S, Kurn H, Aboud AM Al. Secukinumab. Turkderm Turk Arch Dermatol Venereol. 2023;56:52-54. https:\/\/doi.org\/10.4274\/turkderm.galenos.2022.37929","DOI":"10.4274\/turkderm.galenos.2022.37929"},{"issue":"1","key":"1909_CR68","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/J.JAAD.2019.02.068","volume":"81","author":"A Alikhan","year":"2019","unstructured":"Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis suppurativa Foundations: part II: topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81(1):91\u2013101. https:\/\/doi.org\/10.1016\/J.JAAD.2019.02.068.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1909_CR69","doi-asserted-by":"publisher","first-page":"5378","DOI":"10.1111\/BCP.15471","volume":"88","author":"N Ghalandari","year":"2022","unstructured":"Ghalandari N, Crijns HJMJ, Bergman JEH, Dolhain RJEM, van Puijenbroek EP, Hazes JMW. Reported congenital malformations after exposure to non\u2010tumour necrosis factor inhibitor biologics: a retrospective comparative study in EudraVigilance. Br J Clin Pharmacol. 2022;88(12):5378. https:\/\/doi.org\/10.1111\/BCP.15471.","journal-title":"Br J Clin Pharmacol"},{"issue":"16\u201317","key":"1909_CR70","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1080\/1750743X.2024.2401308","volume":"16","author":"RB Shams","year":"2024","unstructured":"Shams RB, Sayed CJ. Bimekizumab for the treatment of Hidradenitis suppurativa. Immunotherapy. 2024;16(16\u201317):1005\u201313. https:\/\/doi.org\/10.1080\/1750743X.2024.2401308.","journal-title":"Immunotherapy"},{"issue":"6","key":"1909_CR71","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1159\/000542217\/4308587\/000542217.PDF","volume":"186","author":"YD Jeong","year":"2025","unstructured":"Jeong YD, Jo H, Cho H, et al. Biologics use for psoriasis during pregnancy and its related adverse outcomes in pregnant women and newborns: findings from WHO pharmacovigilance study. Int Arch Allergy Immunol. 2025;186(6):579\u201393. https:\/\/doi.org\/10.1159\/000542217\/4308587\/000542217.PDF.","journal-title":"Int Arch Allergy Immunol"},{"issue":"11","key":"1909_CR72","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1136\/ANNRHEUMDIS-2017-211384","volume":"76","author":"ME Clowse","year":"2017","unstructured":"Clowse ME, F\u00f6rger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;76(11):1890\u20136. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2017-211384.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1909_CR73","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/ART.40508","volume":"70","author":"MEB Clowse","year":"2018","unstructured":"Clowse MEB, Scheuerle AE, Chambers C, et al. Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database. Arthritis Rheumatol. 2018;70(9):1399\u2013407. https:\/\/doi.org\/10.1002\/ART.40508.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1909_CR74","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1136\/ANNRHEUMDIS-2017-212196","volume":"77","author":"X Mariette","year":"2018","unstructured":"Mariette X, F\u00f6rger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228\u201333. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2017-212196.","journal-title":"Ann Rheum Dis"},{"key":"1909_CR75","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X241311374","author":"P Gisondi","year":"2025","unstructured":"Gisondi P, Montalto E, Curic T, Danese E, Bellinato F, Girolomoni G. Certolizumab pegol in severe hidradenitis suppurativa in pregnancy: a case report. SAGE Open Med Case Rep. 2025. https:\/\/doi.org\/10.1177\/2050313X241311374.","journal-title":"SAGE Open Med Case Rep"},{"key":"1909_CR76","doi-asserted-by":"publisher","DOI":"10.1177\/20406223241257342","author":"A Heidari","year":"2024","unstructured":"Heidari A, Ghane Y, Heidari N, Hosseini S, Goodarzi A. Golimumab and certolizumab pegol for the treatment of hidradenitis suppurativa: a literature review and future perspective. Ther Adv Chronic Dis. 2024. https:\/\/doi.org\/10.1177\/20406223241257342.","journal-title":"Ther Adv Chronic Dis"},{"issue":"3","key":"1909_CR77","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3109\/9781841847665-45","volume":"24","author":"J Strojil","year":"2025","unstructured":"Strojil J, Cifersk\u00e1 H. Certolizumab Pegol. Klinicka Farmakologie a Farmacie. 2025;24(3):155\u201360. https:\/\/doi.org\/10.3109\/9781841847665-45.","journal-title":"Klinicka Farmakologie a Farmacie"},{"key":"1909_CR78","doi-asserted-by":"publisher","unstructured":"Levin EC, Koo JYM, Gottlieb AB. Infliximab. Moderate to severe psoriasis: Fourth Edition. Published online March 21, 2024:231\u2013247. https:\/\/doi.org\/10.1201\/b16633-14","DOI":"10.1201\/b16633-14"},{"issue":"1","key":"1909_CR79","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/JAMADERMATOL.2015.3903","volume":"152","author":"V Tzanetakou","year":"2016","unstructured":"Tzanetakou V, Kanni T, Giatrakou S, et al. Safety and efficacy of anakinra in severe Hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol. 2016;152(1):52\u20139. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2015.3903.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1909_CR80","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1093\/RHEUMATOLOGY\/KEAF387","volume":"64","author":"V Faure-Bardon","year":"2025","unstructured":"Faure-Bardon V, Beghin D, Fautrel B, et al. Exposure during pregnancy to Il-1 targeted therapies and pregnancy, foetal and neonatal outcomes: a study from the French Teratology Information Service. Rheumatol (Oxford). 2025;64(12):6106\u201313. https:\/\/doi.org\/10.1093\/RHEUMATOLOGY\/KEAF387.","journal-title":"Rheumatol (Oxford)"},{"key":"1909_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJOGRB.2025.114553","author":"L Trotta","year":"2025","unstructured":"Trotta L, Mascolo R, Mardygan V, et al. Use of anakinra during pregnancy and breastfeeding in women with recurrent pericarditis: a case series. Eur J Obstet Gynecol Reprod Biol. 2025. https:\/\/doi.org\/10.1016\/J.EJOGRB.2025.114553.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"12","key":"1909_CR82","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1093\/RHEUMATOLOGY\/KEX305","volume":"56","author":"T Youngstein","year":"2017","unstructured":"Youngstein T, Hoffmann P, G\u00fcl A, et al. International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. Rheumatol (Oxford). 2017;56(12):2102\u20138. https:\/\/doi.org\/10.1093\/RHEUMATOLOGY\/KEX305.","journal-title":"Rheumatol (Oxford)"},{"issue":"1","key":"1909_CR83","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/S40259-022-00564-4","volume":"37","author":"A Dernoncourt","year":"2023","unstructured":"Dernoncourt A, Liabeuf S, Bennis Y, et al. Fetal and neonatal adverse drug reactions associated with biologics taken during pregnancy by women with autoimmune diseases: insights from an analysis of the World Health Organization Pharmacovigilance Database (VigiBase\u00ae). BioDrugs. 2023;37(1):73\u201387. https:\/\/doi.org\/10.1007\/S40259-022-00564-4.","journal-title":"BioDrugs"},{"issue":"2-4","key":"1909_CR84","doi-asserted-by":"publisher","first-page":"121","DOI":"10.5603\/RF.110353","volume":"11","author":"K Jab\u0142o\u0144ska","year":"2025","unstructured":"Jab\u0142o\u0144ska K, Kautsch K, Friedman-Gruszczy\u0144ska J, Wolska B, Buda P. Anakinra \u2014 a modern immunomodulatory drug with broad applicability in severe systemic inflammatory reactions \u2014 part 1. History, mechanism of action, pharmacokinetics, side effects, interactions, dosage. Rheumatol Forum. 2025;11(2\u20134):121\u201330. https:\/\/doi.org\/10.5603\/RF.110353.","journal-title":"Rheumatol Forum"},{"issue":"12","key":"1909_CR85","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1093\/RHEUMATOLOGY\/KEX305","volume":"56","author":"T Youngstein","year":"2017","unstructured":"Youngstein T, Hoffmann P, G\u00fcl A, et al. International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. Rheumatol (U K). 2017;56(12):2102\u20138. https:\/\/doi.org\/10.1093\/RHEUMATOLOGY\/KEX305.","journal-title":"Rheumatol (U. K.)"},{"key":"1909_CR86","doi-asserted-by":"publisher","DOI":"10.7573\/DIC.2019-11-6","author":"C Ferreira","year":"2020","unstructured":"Ferreira C, Azevedo A, Nogueira M, Torres T. Management of psoriasis in pregnancy - a review of the evidence to date. Drugs Context. 2020. https:\/\/doi.org\/10.7573\/DIC.2019-11-6.","journal-title":"Drugs Context"},{"issue":"1","key":"1909_CR87","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/J.JAAD.2018.06.046","volume":"80","author":"ARJV Vossen","year":"2019","unstructured":"Vossen ARJV, van Doorn MBA, van der Zee HH, Prens EP. Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial. J Am Acad Dermatol. 2019;80(1):80\u20138. https:\/\/doi.org\/10.1016\/J.JAAD.2018.06.046.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1909_CR88","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1097\/AOG.0000000000003755","volume":"135","author":"EA Peterson","year":"2020","unstructured":"Peterson EA, Lynton J, Bernard A, Santillan MK, Bettendorf B. Rheumatologic medication use during pregnancy: a review. Obstet Gynecol. 2020;135(5):1161. https:\/\/doi.org\/10.1097\/AOG.0000000000003755.","journal-title":"Obstet Gynecol"},{"key":"1909_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/CCID.S583223","volume":"19","author":"F Martora","year":"2026","unstructured":"Martora F, Megna M, Molinelli E, et al. Real-world experience with upadacitinib in patients with atopic dermatitis and hidradenitis suppurativa: a dual-center case series. Clin Cosmet Investig Dermatol. 2026;19:1\u20134. https:\/\/doi.org\/10.2147\/CCID.S583223.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"10","key":"1909_CR90","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/S40264-024-01454-0","volume":"47","author":"U Mahadevan","year":"2024","unstructured":"Mahadevan U, Levy G, Gensler L, et al. Pregnancy outcomes in patients treated with upadacitinib: analysis of data from clinical trials and postmarketing reports. Drug Saf. 2024;47(10):1039\u201349. https:\/\/doi.org\/10.1007\/S40264-024-01454-0.","journal-title":"Drug Saf"},{"key":"1909_CR91","unstructured":"Study Details | NCT05889182 | A study to assess change in disease activity and adverse events of oral upadacitinib in adult and adolescent participants with moderate to severe hidradenitis suppurativa who have failed Anti-tnf therapy | ClinicalTrials.gov. Accessed June 18, 2026. https:\/\/clinicaltrials.gov\/study\/NCT05889182."},{"key":"1909_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/J.CGH.2025.06.007","author":"D Duricova","year":"2026","unstructured":"Duricova D, Sonnenberg E, Augustijns P, et al. Upadacitinib in mothers with inflammatory bowel disease: placental transfer and breast milk excretion. Clin Gastroenterol Hepatol. 2026. https:\/\/doi.org\/10.1016\/J.CGH.2025.06.007.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1909_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/JCM13010034","author":"N Monfared","year":"2023","unstructured":"Monfared N, Gold M, Carbery I, Laube R, Selinger CP. Reproductive safety issues of novel small molecules for the treatment of inflammatory bowel disease: a systematic review. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/JCM13010034.","journal-title":"J Clin Med"},{"issue":"8","key":"1909_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS24086969","volume":"24","author":"R Hambly","year":"2023","unstructured":"Hambly R, Kearney N, Hughes R, Fletcher JM, Kirby B. Metformin treatment of hidradenitis suppurativa: effect on metabolic parameters, inflammation, cardiovascular risk biomarkers, and immune mediators. Int J Mol Sci. 2023;24(8):6969. https:\/\/doi.org\/10.3390\/IJMS24086969.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1909_CR95","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000529359","volume":"9","author":"A Tsentemeidou","year":"2023","unstructured":"Tsentemeidou A, Vakirlis E, Papadimitriou I, Ioannides D, Sotiriou E. Metformin in hidradenitis suppurativa: is it worth pursuing further? Skin Appendage Disord. 2023;9(3):187\u201390. https:\/\/doi.org\/10.1159\/000529359.","journal-title":"Skin Appendage Disord"},{"key":"1909_CR96","doi-asserted-by":"publisher","DOI":"10.1002\/9781119785033.ch2","author":"J Timmons","year":"2023","unstructured":"Timmons J, Boyle J. Metformin. Diabetes Drug Notes. 2023. https:\/\/doi.org\/10.1002\/9781119785033.ch2.","journal-title":"Diabetes Drug Notes"},{"issue":"10","key":"1909_CR97","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/S00592-023-02137-5","volume":"60","author":"L Sciacca","year":"2023","unstructured":"Sciacca L, Bianchi C, Burlina S, et al. Position paper of the Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), and the Italian Study Group of Diabetes in pregnancy: metformin use in pregnancy. Acta Diabetol. 2023;60(10):1421. https:\/\/doi.org\/10.1007\/S00592-023-02137-5.","journal-title":"Acta Diabetol"},{"issue":"10","key":"1909_CR98","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S2213-8587(20)30310-7","volume":"8","author":"DS Feig","year":"2020","unstructured":"Feig DS, Donovan LE, Zinman B, et al. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2020;8(10):834\u201344. https:\/\/doi.org\/10.1016\/S2213-8587(20)30310-7.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"1909_CR99","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1097\/01.AOG.0000163249.65810.5B","volume":"105","author":"GG Briggs","year":"2005","unstructured":"Briggs GG, Ambrose PJ, Nageotte MP, Padilla G, Wan S. Excretion of metformin into breast milk and the effect on nursing infants. Obstet Gynecol. 2005;105(6):1437\u201341. https:\/\/doi.org\/10.1097\/01.AOG.0000163249.65810.5B.","journal-title":"Obstet Gynecol"},{"issue":"11","key":"1909_CR100","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/S00125-002-0939-X","volume":"45","author":"T Hale","year":"2002","unstructured":"Hale T, Kristensen J, Hackett L, Kohan R, Ilett K. Transfer of metformin into human milk. Diabetologia. 2002;45(11):1509\u201314. https:\/\/doi.org\/10.1007\/S00125-002-0939-X.","journal-title":"Diabetologia"},{"issue":"3","key":"1909_CR101","doi-asserted-by":"publisher","DOI":"10.1097\/JW9.0000000000000159","volume":"10","author":"SV Gangidi","year":"2024","unstructured":"Gangidi SV, Greene RK, Olsen E, Jackson S, Nakamura M. Efficacy of spironolactone in treating hidradenitis suppurativa in women of childbearing age: a single-center retrospective analysis. Int J Womens Dermatol. 2024;10(3):e159. https:\/\/doi.org\/10.1097\/JW9.0000000000000159.","journal-title":"Int J Womens Dermatol"},{"issue":"1","key":"1909_CR102","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/S11154-022-09729-6","volume":"24","author":"V Forestiero","year":"2022","unstructured":"Forestiero V, Sconfienza E, Mulatero P, Monticone S. Primary aldosteronism in pregnancy. Rev Endocr Metab Disord. 2022;24(1):39. https:\/\/doi.org\/10.1007\/S11154-022-09729-6.","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"1909_CR103","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/J.JAAD.2018.10.023","volume":"80","author":"W Liszewski","year":"2019","unstructured":"Liszewski W, Boull C. Lack of evidence for feminization of males exposed to spironolactone in utero: a systematic review. J Am Acad Dermatol. 2019;80(4):1147\u20138. https:\/\/doi.org\/10.1016\/J.JAAD.2018.10.023.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1909_CR104","doi-asserted-by":"publisher","DOI":"10.3390\/JCM14113722","volume":"14","author":"E Piotrkowicz","year":"2025","unstructured":"Piotrkowicz E, Skrzypczyk P, Prejbisz A, Dobrowolski P, Gawlak M, Kosi\u0144ski P. Safety and risks of antihypertensive medications during breastfeeding: a review of current guidelines. J Clin Med. 2025;14(11):3722. https:\/\/doi.org\/10.3390\/JCM14113722.","journal-title":"J Clin Med"},{"issue":"2","key":"1909_CR105","doi-asserted-by":"publisher","first-page":"112","DOI":"10.15420\/CFR.2018.21.2","volume":"4","author":"L Kearney","year":"2018","unstructured":"Kearney L, Wright P, Fhadil S, Thomas M. Postpartum cardiomyopathy and considerations for breastfeeding. Card Fail Rev. 2018;4(2):112. https:\/\/doi.org\/10.15420\/CFR.2018.21.2.","journal-title":"Card Fail Rev"},{"issue":"21","key":"1909_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/JCM13216292","volume":"13","author":"PK Krajewski","year":"2024","unstructured":"Krajewski PK, Z\u0142otowska A, Szepietowski JC. The therapeutic potential of GLP-1 receptor agonists in the management of hidradenitis suppurativa: a systematic review of anti-inflammatory and metabolic effects. J Clin Med. 2024;13(21):6292. https:\/\/doi.org\/10.3390\/JCM13216292.","journal-title":"J Clin Med"},{"key":"1909_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2023.1215356","author":"DRP Muller","year":"2023","unstructured":"Muller DRP, Stenvers DJ, Malekzadeh A, Holleman F, Painter RC, Siegelaar SE. Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence. Front Endocrinol (Lausanne). 2023. https:\/\/doi.org\/10.3389\/FENDO.2023.1215356.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"1909_CR108","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1001\/JAMAINTERNMED.2023.6663","volume":"184","author":"CE Cesta","year":"2024","unstructured":"Cesta CE, Rotem R, Bateman BT, et al. Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy. JAMA Intern Med. 2024;184(2):144\u201352. https:\/\/doi.org\/10.1001\/JAMAINTERNMED.2023.6663.","journal-title":"JAMA Intern Med"},{"issue":"6S","key":"1909_CR109","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/J.JAAD.2024.09.015","volume":"91","author":"FE Fonjungo","year":"2024","unstructured":"Fonjungo FE, Barnes LA, Aleshin MA. Antibiotic, hormonal\/metabolic, and retinoid therapies for hidradenitis suppurativa. J Am Acad Dermatol. 2024;91(6S):S37\u201341. https:\/\/doi.org\/10.1016\/J.JAAD.2024.09.015.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1909_CR110","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/S40257-022-00725-9","volume":"23","author":"K Bouwman","year":"2022","unstructured":"Bouwman K, Aarts P, Dudink K, et al. Drug survival of oral retinoids in hidradenitis suppurativa: a real-life cohort study. Am J Clin Dermatol. 2022;23(6):905. https:\/\/doi.org\/10.1007\/S40257-022-00725-9.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1909_CR111","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/IJD.16953","volume":"63","author":"Z T\u0131rm\u0131k\u00e7\u0131o\u011flu","year":"2024","unstructured":"T\u0131rm\u0131k\u00e7\u0131o\u011flu Z, Tatl\u0131parmak A. Face-to-face: isotretinoin use and pregnancy outcome. Int J Dermatol. 2024;63(2):232\u20138. https:\/\/doi.org\/10.1111\/IJD.16953.","journal-title":"Int J Dermatol"},{"issue":"6","key":"1909_CR112","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/J.ARD.2025.02.023","volume":"84","author":"L R\u00fcegg","year":"2025","unstructured":"R\u00fcegg L, Pluma A, Hamroun S, et al. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Ann Rheum Dis. 2025;84(6):910\u201326. https:\/\/doi.org\/10.1016\/J.ARD.2025.02.023.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1909_CR113","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1159\/000517283","volume":"238","author":"JR Seivright","year":"2022","unstructured":"Seivright JR, Villa NM, Grogan T, et al. Impact of pregnancy on hidradenitis suppurativa disease course: a systematic review and meta-analysis. Dermatology (Basel). 2022;238(2):260\u20136. https:\/\/doi.org\/10.1159\/000517283.","journal-title":"Dermatology (Basel)"},{"issue":"9","key":"1909_CR114","doi-asserted-by":"publisher","DOI":"10.7759\/CUREUS.45370","volume":"15","author":"SD Nalla","year":"2023","unstructured":"Nalla SD, Kurakula S, Siddaraju MN. A rare case of pregnancy after surgical treatment for stage III Hidradenitis suppurativa. Cureus. 2023;15(9):e45370. https:\/\/doi.org\/10.7759\/CUREUS.45370.","journal-title":"Cureus"},{"key":"1909_CR115","doi-asserted-by":"publisher","DOI":"10.1177\/09760016251314958","author":"OM Jacob","year":"2025","unstructured":"Jacob OM, Sharmila V, Garkapati K. Hidradenitis suppurativa in pregnancy: a case report and clinical insights. Apollo Med. 2025. https:\/\/doi.org\/10.1177\/09760016251314958.","journal-title":"Apollo Med"},{"key":"1909_CR116","doi-asserted-by":"publisher","DOI":"10.1093\/CED\/LLAF515","author":"YN Chen","year":"2026","unstructured":"Chen YN, Shen CH, Tai CC, Wang TY, Chi CC. Adverse pregnancy outcomes among pregnant women with hidradenitis suppurativa: a systematic review and meta-analysis. Clin Exp Dermatol. 2026. https:\/\/doi.org\/10.1093\/CED\/LLAF515.","journal-title":"Clin Exp Dermatol"},{"issue":"9","key":"1909_CR117","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/J.BJPS.2018.05.016","volume":"71","author":"N Jakharia-Shah","year":"2018","unstructured":"Jakharia-Shah N, Chadha P, Watson L. A review of the safety of common aesthetic procedures during pregnancy. J Plast Reconstr Aesthet Surg. 2018;71(9):1362\u201380. https:\/\/doi.org\/10.1016\/J.BJPS.2018.05.016.","journal-title":"J Plast Reconstr Aesthet Surg"},{"issue":"2","key":"1909_CR118","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4103\/JCAS.JCAS_226_20","volume":"15","author":"A Garg","year":"2022","unstructured":"Garg A, Mysore V. Dermatologic and cosmetic procedures in pregnancy. J Cutan Aesthet Surg. 2022;15(2):108\u201317. https:\/\/doi.org\/10.4103\/JCAS.JCAS_226_20.","journal-title":"J Cutan Aesthet Surg"},{"issue":"5","key":"1909_CR119","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1089\/FPSAM.2023.0326","volume":"26","author":"C Hudson","year":"2024","unstructured":"Hudson C, Wilson P, Lieberman D, Mittelman H, Parikh S. Analysis of breast milk samples in lactating women after undergoing botulinum toxin injections for facial rejuvenation: a pilot study. Facial Plast Surg Aesthet Med. 2024;26(5):523\u20136. https:\/\/doi.org\/10.1089\/FPSAM.2023.0326.","journal-title":"Facial Plast Surg Aesthet Med"},{"issue":"10443","key":"1909_CR120","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","volume":"403","author":"AB Kimball","year":"2024","unstructured":"Kimball AB, Jemec GBE, Sayed CJ, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet. 2024;403(10443):2504\u201319. https:\/\/doi.org\/10.1016\/S0140-6736(24)00101-6.","journal-title":"Lancet"},{"key":"1909_CR121","unstructured":"Study Details | NCT05355805 | Hidradenitis suppurativa phase 2b study of izokibep | ClinicalTrials.gov. Accessed March 2, 2026. https:\/\/clinicaltrials.gov\/study\/NCT05355805."},{"issue":"1","key":"1909_CR122","doi-asserted-by":"publisher","first-page":"2209920","DOI":"10.1080\/19420862.2023.2209920","volume":"15","author":"S Klint","year":"2023","unstructured":"Klint S, Feldwisch J, Gudmundsdotter L, et al. Izokibep: preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis. MAbs. 2023;15(1):2209920. https:\/\/doi.org\/10.1080\/19420862.2023.2209920.","journal-title":"MAbs"},{"key":"1909_CR123","unstructured":"Study Details | NCT06645821 | Participants with mild to moderate Hidradenitis suppurativa will receive EVO101 a topical cream 0.1% | ClinicalTrials.gov. Accessed March 2, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06645821."},{"issue":"12","key":"1909_CR124","doi-asserted-by":"publisher","first-page":"45","DOI":"10.37667\/pk.2019.1094","volume":"41","author":"IS Padda","year":"2024","unstructured":"Padda IS, Bhatt R, Patel P, Parmar M. Upadacitinib. Pharma-Kritik. 2024;41(12):45\u20138. https:\/\/doi.org\/10.37667\/pk.2019.1094.","journal-title":"Pharma-Kritik"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01909-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01909-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01909-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:02:36Z","timestamp":1793016156000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01909-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":124,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1909"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01909-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"15 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mi\u0142osz Lewandowski; Wiktoria Szablewska; Martyna S\u0142awi\u0144ska; Roman J. Nowicki; Aleksandra Kujach; Wioletta Bara\u0144ska-Rybak have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}